Francis Creighton, MD
Otolaryngology · Baltimore, MDNPI 1871859959
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,000 of the $6,615 with a category attached, or 60.5%. Amgen accounts for 60.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $4,000 and has fallen 53.3% since, to $1,867 in 2024. Among otolaryngology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 19 payments — averaging $348.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Med-el Corporation$2K
- Cochlear Americas$518
- Medical Device Business Services, Inc.$208
- Eli Lilly$143
- Acclarent, Inc$23
Across 1 payment — averaging $2434.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cochlear Americas$2K
What the payments were for
- Consulting fees$1,70026%
- Speaking & faculty fees$4,00060%
- Travel & lodging$5008%
- Food & beverage$4166%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $4,000 |
| Med-el Corporation | 3 | $1,724 |
| Cochlear Americas | 9 | $518 |
| Medical Device Business Services, Inc. | 3 | $208 |
| Eli Lilly | 1 | $143 |
| Acclarent, Inc | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$4,000
- Nucleus$294
- Baha$294
- MATRIXCOMBO$179
How this compares
$6,615 in reported general payments places this provider in the 90th percentile of 222 otolaryngology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ofloxacin | 12 | $526 |
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 13 | $514 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Baltimore
- Marc DubinBaltimore$350K
- Patrick HaBaltimore$41K
- Andrew LaneBaltimore$34K
- Jean KimBaltimore$29K
- Nicholas RowanBaltimore$25K
- Rodney TaylorBaltimore$18K
- Kyle HattenBaltimore$12K
- Alexander HillelBaltimore$11K
- Carole FakhryBaltimore$11K
- Lee AkstBaltimore$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.